Discover investment opportunities in AI Pharmaceutical Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in AI Pharmaceutical Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in AI Pharmaceutical Stocks using our Smart AI Filter.
8 stocks found for "AI Pharmaceutical Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.89 Risk measure | ±41.9% Price volatility | 22.8 Valuation | 0.00% Annual yield | |||
0.30 Risk measure | ±26.0% Price volatility | 12.1 Valuation | 0.66% Annual yield | |||
0.49 Risk measure | ±19.6% Price volatility | 26.1 Valuation | 1.76% Annual yield | |||
0.83 Risk measure | ±70.5% Price volatility | -3.5 Valuation | 0.00% Annual yield | |||
1.24 Risk measure | ±27.6% Price volatility | 13.6 Valuation | 0.00% Annual yield | |||
0.32 Risk measure | ±24.8% Price volatility | 8.7 Valuation | 6.75% Annual yield | |||
1.19 Risk measure | ±53.7% Price volatility | -156.9 Valuation | 0.00% Annual yield | |||
0.36 Risk measure | ±26.9% Price volatility | 24.5 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
In the most recent trading session, Moderna (MRNA) closed at $31.25, indicating a -2.95% shift from the previous trading day.
Read moreEylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
Read moreAbbott (ABT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Read moreGet a deeper insight into the potential performance of IQVIA (IQV) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Read moreIllumina Inc. ILMN is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond short-term price action and offers compelling reasons why this stock should be avoided.
Read moreJared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Read more